Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)

Inclusion Criteria: * Postmenopausal women (≥ 12 months of amenorrhea or FSH ≥ 40 after hysterectomy with bilateral oophorectomy) who receive β3 adrenergic receptors (mirabegron 50 mg) treatment for OAB * Overactive bladder syndrome (OAB) * ≥ 3 months symptoms of urgency, with or without urinary incontinence, and ≥ 8 micturitions / 24h * At least 3 episodes of urgent urination (3rd-4th grade) as recorded in the patient perception intensity of urgency scale (PPiUS) during a 3 day urination calendar , with or without urinary incontinence. Exclusion Criteria: * Participants with: * Pelvic Organ Prolapse (POP) \> stage II of the pelvic organ prolapse quantitation system (POP-Q) * Post void residual volume \> 200 ml (measured by ultrasound) * Use of moisturizers or lubricants the last month * Use of vaginal estrogen in the last 6 months * Use of drugs for urinary incontinence * Use of psychotropic drugs * Symptomatic urinary tract infection * Active genital infection * Kidney or liver disease * Abnormal cardiac conduction, rate or rythm disorders * Diabetic neuropathy * Myasthenia gravis * History of malignant disease * Previous radio-chemo therapy